Focused On-demand Library for Transcription termination factor 3, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96E29

UPID:

MTEF3_HUMAN

Alternative names:

Mitochondrial transcription termination factor 3; mTERF domain-containing protein 1, mitochondrial

Alternative UPACC:

Q96E29; B3KMG6; G3V130; Q9Y301

Background:

Transcription termination factor 3, mitochondrial, also known as mitochondrial transcription termination factor 3 or mTERF domain-containing protein 1, mitochondrial, plays a pivotal role in mitochondrial transcription and translation. It is essential for the normal assembly of mitochondrial respiratory complexes and overall mitochondrial function. This protein ensures the maintenance of 16S rRNA levels and is crucial in mitochondrial ribosome assembly, specifically in the biogenesis of the 39S ribosomal subunit.

Therapeutic significance:

Understanding the role of Transcription termination factor 3, mitochondrial could open doors to potential therapeutic strategies.